{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:22:53Z","timestamp":1790623373270,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MHC"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ctrv.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T12:53:39Z","timestamp":1519908819000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians"],"prefix":"10.1016","volume":"65","author":[{"given":"Sophie","family":"Outh-Gauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Broudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandre","family":"Gasne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Denize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Mirghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Badoual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.02.008_b0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0010","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8 + T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2018.02.008_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2018.02.008_b0020","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2018.02.008_b0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2018.02.008_b0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/cmi.2010.28","article-title":"Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer","volume":"7","author":"Zhang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0050","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur J Immunol"},{"issue":"181","key":"10.1016\/j.ctrv.2018.02.008_b0055","first-page":"6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"2008","author":"Kinter","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.ctrv.2018.02.008_b0060","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7\u2013H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0070","series-title":"WHO classification of head and neck tumours","year":"2017"},{"key":"10.1016\/j.ctrv.2018.02.008_b0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.02.008_b0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/imt.10.32","article-title":"Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"2","author":"Alexandroff","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2018.02.008_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6009","article-title":"The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck","volume":"31","author":"Hayes","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0090","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0095","unstructured":"Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumors. World Health Organisation Classification of Tumors. IARC, Lyon, 2005."},{"key":"10.1016\/j.ctrv.2018.02.008_b0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annpat.2016.12.013","article-title":"Current events in immunotherapy for upper aerodigestive tract cancer","volume":"37","author":"Outh-Gauer","year":"2017","journal-title":"Ann Pathol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-05-1886","article-title":"Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers","volume":"12","author":"Badoual","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-9-4","article-title":"Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer","volume":"110","author":"Ward","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0125","doi-asserted-by":"crossref","unstructured":"Welters MJP, Ma W, Santegoets SJ, Goedemans R, Ehsan I, Jordanova ES, et al. Intratumoral HPV16-specific T-cells constitute a type 1 oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res 2017:clincanres.2140.2017. http:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2140.","DOI":"10.1158\/1078-0432.CCR-17-2140"},{"key":"10.1016\/j.ctrv.2018.02.008_b0130","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.oraloncology.2014.04.003","article-title":"The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck","volume":"50","author":"Zandberg","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed death ligand-1 immunohistochemistry: friend or Foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2018.02.008_b0140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0145","article-title":"Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis","author":"Li","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0150","first-page":"527","article-title":"Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res Treat Off J Korean Cancer Assoc"},{"key":"10.1016\/j.ctrv.2018.02.008_b0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12105-012-0406-z","article-title":"B7\u2013H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma","volume":"7","author":"Ukpo","year":"2013","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0160","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2018.02.008_b0165","doi-asserted-by":"crossref","first-page":"E1625","DOI":"10.1002\/hed.24290","article-title":"Molecular profiling of head and neck squamous cell carcinoma","volume":"38","author":"Feldman","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2018.02.008_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0175","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10163","article-title":"Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas","author":"Sablin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.02.008_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","article-title":"Novel technologies and emerging biomarkers for personalized cancer immunotherapy","volume":"4","author":"Yuan","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0185","doi-asserted-by":"crossref","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124\u2013128. http:\/\/doi.org\/10.1126\/science.aaa1348.","DOI":"10.1126\/science.aaa1348"},{"key":"10.1016\/j.ctrv.2018.02.008_b0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.oraloncology.2016.08.001","article-title":"The role of antagonists of the PD-1:PD-L1\/PD-L2 axis in head and neck cancer treatment","volume":"61","author":"Pai","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0200","doi-asserted-by":"crossref","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7\u2013h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37. http:\/\/doi.org\/10.1126\/scitranslmed.3003689.","DOI":"10.1126\/scitranslmed.3003689"},{"key":"10.1016\/j.ctrv.2018.02.008_b0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.imbio.2011.10.016","article-title":"Interferon-\u03b3-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway","volume":"217","author":"Chen","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ctrv.2018.02.008_b0210","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","article-title":"Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFN\u03b3 that induce PD-L1 expression in head and neck cancer","volume":"76","author":"Concha-Benavente","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0215","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0220","doi-asserted-by":"crossref","first-page":"e965570","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2018.02.008_b0225","doi-asserted-by":"crossref","first-page":"35484","DOI":"10.1074\/jbc.M112.367532","article-title":"Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients","volume":"287","author":"Li","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2018.02.008_b0230","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4161\/onci.18852","article-title":"Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer","volume":"1","author":"Pere","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ctrv.2018.02.008_b0235","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.02.008_b0240","doi-asserted-by":"crossref","first-page":"e94273","DOI":"10.1371\/journal.pone.0094273","article-title":"Markers of epithelial to mesenchymal transition in association with survival in Head and Neck Squamous Cell Carcinoma (HNSCC)","volume":"9","author":"Pectasides","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ctrv.2018.02.008_b0245","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","article-title":"Epithelial-mesenchymal plasticity: a central regulator of cancer progression","volume":"25","author":"Ye","year":"2015","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0250","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1158\/1541-7786.MCR-11-0271","article-title":"IL-6 Promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway","volume":"9","author":"Yadav","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.scr.2016.02.028","article-title":"CD44highCD24low molecular signature determines the cancer stem cell and EMT phenotype in oral squamous cell carcinoma","volume":"16","author":"Ghuwalewala","year":"2016","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0260","first-page":"640","article-title":"The relationship between EMT, CD44(high) \/EGFR(low) phenotype, and treatment response in head and neck cancer cell lines","volume":"45","author":"Johansson","year":"2016","journal-title":"J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0265","doi-asserted-by":"crossref","first-page":"15901","DOI":"10.18632\/oncotarget.7431","article-title":"PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma","volume":"7","author":"Ock","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.02.008_b0270","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-15-2665","article-title":"CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1","volume":"22","author":"Lee","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/156800910790980197","article-title":"Stat3 orchestrates tumor development and progression: the achilles heel of head and neck cancers?","volume":"10","author":"Masuda","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ctrv.2018.02.008_b0280","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-06-3047","article-title":"Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma","volume":"13","author":"Allen","year":"2007","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0285","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-04-0054","article-title":"Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck","volume":"10","author":"Kuss","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0290","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-05-2750","article-title":"Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer","volume":"12","author":"Ferris","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0295","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1158\/0008-5472.CAN-07-6842","article-title":"The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer","volume":"68","author":"Badoual","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0300","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/bjc.2013.645","article-title":"Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients","volume":"109","author":"Jie","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b0305","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.02.008_b0315","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","article-title":"Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma","volume":"47","author":"Cho","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0320","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2015.09.006","article-title":"Negative regulation of natural killer cell in tumor tissue and peripheral blood of oral squamous cell carcinoma","volume":"76","author":"Dutta","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.ctrv.2018.02.008_b0325","doi-asserted-by":"crossref","first-page":"e1151594","DOI":"10.1080\/2162402X.2016.1151594","article-title":"CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma","volume":"5","author":"Yu","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2018.02.008_b0330","doi-asserted-by":"crossref","first-page":"42067","DOI":"10.18632\/oncotarget.5955","article-title":"PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47\/SIRP\u03b1 axis in HPV negative head and neck squamous cell carcinoma","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.02.008_b0335","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1038\/cti.2016.16","article-title":"OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer","volume":"5","author":"Montler","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0340","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.02.008_b0345","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","author":"Chow","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0355","doi-asserted-by":"crossref","unstructured":"Gillison, ML. Nivolumab (nivo) vs investigator\u2019s choice (IC) for recurrent or metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141\u201d, [Abstract CT099]. In: Proc 107th Annu Meet Am Assoc Cancer Res New Orleans Phila PA; 2016.","DOI":"10.1158\/1538-7445.AM2016-CT099"},{"key":"10.1016\/j.ctrv.2018.02.008_b0360","doi-asserted-by":"crossref","unstructured":"Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn M, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): Phase 3 KEYNOTE-040 trial. LBA45_PR, Madrid; 2017.","DOI":"10.1093\/annonc\/mdx440.040"},{"key":"10.1016\/j.ctrv.2018.02.008_b0365","doi-asserted-by":"crossref","unstructured":"Zandberg DP, Jarkowski A, Emeribe UA, Goswami T, Melillo G. A phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530). J Clin Oncol 2015;33:TPS6086-TPS6086. http:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.tps6086.","DOI":"10.1200\/jco.2015.33.15_suppl.tps6086"},{"key":"10.1016\/j.ctrv.2018.02.008_b0370","doi-asserted-by":"crossref","unstructured":"Hsu C, Lee S-H, Ejadi S, Even C, Cohen R, Le Tourneau C, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: interim results from a phase 1b study. Ann Oncol 2015;26:ix94.1\u2013ix94. http:\/\/doi.org\/10.1093\/annonc\/mdv527.02.","DOI":"10.1093\/annonc\/mdv527.02"},{"key":"10.1016\/j.ctrv.2018.02.008_b0375","doi-asserted-by":"crossref","unstructured":"Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1\u2013positive nasopharyngeal carcinoma: results of the KEYNOTE-028 Study. J Clin Oncol 2017:JCO.2017.73.3675. http:\/\/doi.org\/10.1200\/JCO.2017.73.3675.","DOI":"10.1200\/JCO.2017.73.3675"},{"key":"10.1016\/j.ctrv.2018.02.008_b0380","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.02.008_b0385","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0390","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0395","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0400","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11864-016-0419-z","article-title":"Checkpoint inhibitors in head and neck cancer: rationale, clinical activity, and potential biomarkers","volume":"17","author":"Economopoulou","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0405","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","article-title":"Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection?","volume":"76","author":"Festino","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2018.02.008_b0410","doi-asserted-by":"crossref","unstructured":"Hsu M-C, Hsiao J-R, Chang K-C, Wu Y-H, Su I-J, Jin Y-T, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol Off J U S Can Acad Pathol Inc 2010;23:1393\u2013403. http:\/\/doi.org\/10.1038\/modpathol.2010.130.","DOI":"10.1038\/modpathol.2010.130"},{"key":"10.1016\/j.ctrv.2018.02.008_b0415","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","article-title":"Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma","volume":"32","author":"Zhang","year":"2015","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"10.1016\/j.ctrv.2018.02.008_b0420","doi-asserted-by":"crossref","first-page":"e0157969","DOI":"10.1371\/journal.pone.0157969","article-title":"Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma","volume":"11","author":"Lee","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2018.02.008_b0425","doi-asserted-by":"crossref","first-page":"13060","DOI":"10.18632\/oncotarget.7421","article-title":"Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.02.008_b0430","doi-asserted-by":"crossref","unstructured":"Seiwert TY, Burtness B, Weiss J. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. vol. 33. ASCO Meeting: J Clin Oncol, (suppl; abstr 6017); 2015.","DOI":"10.1200\/jco.2015.33.15_suppl.6017"},{"key":"10.1016\/j.ctrv.2018.02.008_b0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6010","article-title":"Biomarkers and response to pembrolizumab (pembro) in recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0440","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2018.02.008_b0445","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.6009","article-title":"Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC)","volume":"35","author":"Haddad","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0450","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.6049","article-title":"Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs)","volume":"35","author":"Seiwert","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.02.008_b0455","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.02.008_b0460","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1(+)CD8(+) T cells correlates with poor clinical outcome in renal cell carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0465","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1158\/0008-5472.CAN-16-3167","article-title":"PD-1 Status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer","volume":"77","author":"Kansy","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0470","doi-asserted-by":"crossref","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2018.02.008_b0475","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1078-0432.CCR-14-0202","article-title":"Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS","volume":"21","author":"Yoshitake","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0480","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-15-2364","article-title":"Resident memory t cells as surrogate markers of the efficacy of cancer vaccines","volume":"22","author":"Nizard","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0485","doi-asserted-by":"crossref","unstructured":"Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, et al. Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines 2016;4. http:\/\/doi.org\/10.3390\/vaccines4040037.","DOI":"10.3390\/vaccines4040037"},{"key":"10.1016\/j.ctrv.2018.02.008_b0490","doi-asserted-by":"crossref","unstructured":"Glisson B, Massarelli E, William WN, Johnson FM, Kies MS, Ferrarotto R, et al. Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer; 2017.","DOI":"10.1093\/annonc\/mdx376.002"},{"key":"10.1016\/j.ctrv.2018.02.008_b0495","doi-asserted-by":"crossref","unstructured":"Sandoval F, Terme M, Nizard M, Badoual C, Bureau M-F, Freyburger L, et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013;5:172ra20. http:\/\/doi.org\/10.1126\/scitranslmed.3004888.","DOI":"10.1126\/scitranslmed.3004888"},{"key":"10.1016\/j.ctrv.2018.02.008_b0500","doi-asserted-by":"crossref","first-page":"15221","DOI":"10.1038\/ncomms15221","article-title":"Induction of resident memory T cells enhances the efficacy of cancer vaccine","volume":"8","author":"Nizard","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2018.02.008_b0505","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1535-7163.MCT-14-1015","article-title":"Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer","volume":"14","author":"Mondini","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2018.02.008_b0510","first-page":"1093","article-title":"Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations","volume":"8","author":"Strome","year":"2002","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2018.02.008_b0515","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.02.008_b9000","doi-asserted-by":"crossref","first-page":"43627","DOI":"10.1038\/srep43627","article-title":"PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T21:48:06Z","timestamp":1603921686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":104,"alternative-id":["S0305737218300185"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}